Table 3

Pre-dose pulmonary function measurements at the end of each 2‐week treatment period

PlaceboSalmeterol
FEV1 L1.03±0.08 (40)1.17±0.09 (45)**
FVC L2.25±0.12 (60)2.48±0.12 (67)**
FEV1/FVC %45±2 (65)46±2 (66)
PEFR L·s−13.35±0.23 (63)3.75±0.20 (71)*
FEF50% L·s−10.46±0.05 (12)0.53±0.06 (14)*
FIF50% L·s−12.94±0.253.26±0.28*
TLC L7.31±0.26 (122)7.25±0.27 (121)
IC L1.74±0.11 (62)1.96±0.11 (70)**
FRC L5.57±0.24 (173)5.29±0.24 (165)**
SVC L2.66±0.14 (71)2.83±0.14 (76)*
RV L4.65±0.21 (216)4.42±0.23 (206)*
DL,CO/VA mL·min−1·mmHg−1·L−13.08±0.18 (82)3.00±0.18 (79)
MIP cmH2O50±5 (62)52±5 (65)
  • Data are presented as mean±sem (per cent predicted)

  • FEV1: forced expiratory volume in one second

  • FVC: forced vital capacity

  • PEFR: peak expiratory flow rate

  • FEF50%: forced expiratory flow when 50% of the FVC has been exhaled

  • FIF50%: forced inspiratory flow when 50% of the FVC has been exhaled

  • TLC: total lung capacity

  • IC: inspiratory capacity

  • FRC: functional residual capacity

  • SVC: slow expiratory vital capacity

  • RV: residual volume

  • DL,CO: single-breath diffusing capacity of the lung for carbon monoxide

  • VA: alveolar volume

  • MIP: maximal inspiratory mouth occlusion pressure

  • *, **: p<0.05, p<0.01: versus placebo

  • 1 mmHg=0.133 kPa